
UCB scores Japanese approval for seizure therapy, Vimpat
pharmafile | July 5, 2016 | News story | Manufacturing and Production, Research and Development | Daiichi Sankyo, Japan, UCB, japanese
UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in the treatment of partial onset seizures in adult patients with epilepsy in Japan.
Vimpat is approved in this indication in both the US and the EU. New trial data released last year suggested that UCB would seek approval for the drug as a monotherapy in the EU at some stage this year.
The Belgian pharmaceutical company agreed a deal to partner with Daiichi Sankyo on the commercialisation of Vimpat in Japan in 2014. Patients who have not obtained sufficient response to other antiepileptic drugs will now be able to access Vimpat.
Jean-Christophe Teller, CEO at UCB, says: “This is an example of our collaborative, patient-led and science-driven approach delivering benefits by providing additional treatment options for patients living with epilepsy. We look forward to successfully launching lacosamide in Japan and continuing our excellent relationship with Daiichi Sankyo.”
Joji Nakayama, president and CEO at Daiichi Sankyo, comments: “Lacosamide’s well-established efficacy and tolerability profile will provide doctors in Japan and their patients with an additional treatment option to help manage their condition.”
Sean Murray
Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …






